Relmada Historical Income Statement
| RLMD Stock | USD 0.27 0.01 3.57% |
Historical analysis of Relmada Therapeutics income statement accounts such as Other Operating Expenses of 125.2 M, Ebitda of 4.6 M, Cost Of Revenue of 1.1 K or Total Operating Expenses of 125.2 M can show how well Relmada Therapeutics performed in making a profits. Evaluating Relmada Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Relmada Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Relmada Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Relmada Therapeutics is a good buy for the upcoming year.
Relmada |
About Relmada Income Statement Analysis
Relmada Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Relmada Therapeutics shareholders. The income statement also shows Relmada investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Relmada Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Relmada Therapeutics. It is also known as Relmada Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Relmada Therapeutics income statement and represents the costs associated with goods and services Relmada Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Relmada Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Relmada Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.At present, Relmada Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Selling And Marketing Expenses is expected to grow to about 14.9 M, whereas Operating Income is projected to grow to (88.7 M).
| 2024 | 2025 (projected) | Total Operating Expenses | 119.3M | 125.2M | Cost Of Revenue | 1.1K | 1.1K |
Relmada Therapeutics income statement Correlations
Click cells to compare fundamentals
Relmada Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Relmada Therapeutics income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 3.8K | 1.3K | 2K | 103.7M | 119.3M | 125.2M | |
| Selling General Administrative | 24.9M | 35.1M | 47.9M | 48.9M | 56.2M | 59.0M | |
| Other Operating Expenses | 60.8M | 125.7M | 161.2M | 103.7M | 119.3M | 125.2M | |
| Operating Income | (60.8M) | (125.7M) | (161.2M) | (103.7M) | (93.3M) | (88.7M) | |
| Ebit | (59.5M) | (125.8M) | (157.0M) | (98.8M) | (88.9M) | (84.5M) | |
| Ebitda | (59.5M) | (125.8M) | (157.0M) | 4.9M | 4.4M | 4.6M | |
| Total Operating Expenses | 60.8M | 125.7M | 161.2M | 103.7M | 119.3M | 125.2M | |
| Income Before Tax | (59.5M) | (125.8M) | (157.0M) | (98.8M) | (88.9M) | (84.5M) | |
| Total Other Income Expense Net | 1.4M | (48.3K) | 4.2M | 4.9M | 5.6M | 5.9M | |
| Net Income | (59.5M) | (125.8M) | (157.0M) | (98.8M) | (88.9M) | (84.5M) | |
| Income Tax Expense | (1.4M) | 48.3K | (2.7M) | (103.7K) | (119.3K) | (125.2K) | |
| Research Development | 36.0M | 90.6M | 113.3M | 54.8M | 63.0M | 36.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.